^
Association details:
| Biomarker: | SRC T341I |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
Confirming the specificity of the rescue, SRCT341I cells also showed increased resistance to saracatinib and bosutinib, but not ponatinib, which is designed to overcome this gatekeeper mutation.
DOI:
10.1158/2159-8290.CD-15-1442
